Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing both insulin and dasiglucagon. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Earnings for Zealand Pharma A/S (ZEAL.CO)
Earnings in 2023 (TTM): $-100,248,119
According to Zealand Pharma A/S's latest financial reports the company's current earnings (TTM) are $-100,248,119. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Zealand Pharma A/S
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-100,248,119 | $-99,523,197 |
| 2022 | $-137,466,629 | $-136,557,153 |
| 2021 | $-145,230,479 | $-143,987,250 |
| 2020 | $-118,744,238 | $-119,744,930 |
| 2019 | $-81,554,012 | $-80,827,676 |
| 2018 | $88.4 M | $82.21 M |
| 2017 | $-39,282,544 | $-38,504,730 |
| 2016 | $-22,543,859 | $-21,766,046 |
| 2015 | $-16,946,714 | $-16,115,868 |
| 2014 | $-10,251,580 | $-9,190,925 |
| 2013 | $-25,975,572 | $-25,987,027 |
| 2012 | $5.14 M | $5.14 M |
| 2011 | $1.89 M | $963.5 K |
| 2010 | $-14,797,404 | $-14,797,404 |
| 2009 | $-10,706,954 | $-11,317,750 |
| 2008 | $-4,770,400 | $-4,770,400 |
| 2007 | $-7,778,133 | $-7,778,133 |